The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results.
Jaafar Bennouna
Consultant or Advisory Role - Pierre Fabre Medicament
Honoraria - Pierre Fabre Medicament
Libor Havel
No relevant relationships to disclose
Maciej Krzakowski
No relevant relationships to disclose
Jens Kollmeier
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly (U); Pfizer (U); Roche (U)
Radj Gervais
No relevant relationships to disclose
Eric Dansin
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Monika Serke
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Novartis; Pierre Fabre Medicament; Roche
Honoraria - Boehringer Ingelheim; Lilly; Novartis; Pierre Fabre Medicament; Roche
Adolfo G. Favaretto
No relevant relationships to disclose
Manuel Cobo
No relevant relationships to disclose
Aleksandra Szczesna
No relevant relationships to disclose
Libero Ciuffreda
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Mario Nicolini
No relevant relationships to disclose
Rodryg Ramlau
No relevant relationships to disclose
Domenico Amoroso
No relevant relationships to disclose
Barbara Melotti
No relevant relationships to disclose
Teresa Almodovar
Consultant or Advisory Role - Pfizer (U); Roche (U)
Honoraria - Lilly
Nathalie Vaissiere
Employment or Leadership Position - Pierre Fabre Medicament
Marcello Riggi
Employment or Leadership Position - Pierre Fabre Medicament
Eng Huat Tan
No relevant relationships to disclose